Nuvalent, Inc (NUVL) Stock Analysis
Verdict: AVOID
A wave of institutional downgrades and aggressive insider selling suggests the clinical bull case is fully priced at $123.
Investment score: 38/100
Analysis as of
Is Nuvalent, Inc stock worth reviewing? The TradeMates thesis
NUVL has reached a valuation milestone that the market is currently unwilling to exceed, evidenced by five simultaneous downgrades. While the science remains promising, the financial profile—marked by zero revenue, deepening losses ($425M net loss in 2025), and aggressive insider selling—makes the current entry point high-risk with minimal immediate upside.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Nuvalent, Inc opportunities and risks
What speaks for NUVL
- First-in-Class Potential for NVL-520
What speaks against NUVL
- Institutional Sentiment Reversal
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NUVL | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.4% |
| BMRN | 41.5x | 3.5x | 21.6x | 75.9% | 8.3% | 6.9% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.6% |
| MDGL | n/a | 9.7x | n/a | 93.1% | -27.3% | -2.5% |
| ARWR | n/a | 16.6x | n/a | 100.0% | -48.4% | -0.5% |
| KRYS | 40.3x | 21.9x | 46.5x | 92.8% | 53.9% | 2.6% |
| Peer median | n/a | 9.7x | n/a | 92.8% | 0.0% | -0.5% |
Frequently asked questions about Nuvalent, Inc (NUVL)
Is NUVL stock a good investment?
The TradeMates model rates Nuvalent, Inc as AVOID with an investment score of 38/100. NUVL has reached a valuation milestone that the market is currently unwilling to exceed, evidenced by five simultaneous downgrades. While the science remains promising, the financial profile—marked by zero revenue, deepening losses ($425M net loss in 2025), and aggressive insider selling—makes the current entry point high-risk with minimal immediate upside. This is algorithmic model output, not personal investment advice.
Is NUVL stock a buy?
The TradeMates model verdict for NUVL is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.